5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Prostate Cancer Diagnostics and Therapy Market is segmented by Type, Modality, and Geography.
Fastest Growing Market:
The prostate cancer diagnostics and therapy market is expected to register a CAGR of nearly 6.1% during the forecast period, 2019-2024.
The prostate gland is located in the pelvis, below the bladder and in front of the rectum. Prostate cancer begins when normal cells in the prostate begin to multiply uncontrollably. The scope of the study is limited to revenue generated by various diagnostic and therapeutic products used in the management of benign prostatic hyperplasia, prostatic adenocarcinoma, and small cell carcinoma, among other types of prostate cancer.
|Benign Prostatic Hyperplasia|
|Small Cell Carcinoma|
Report scope can be customized per your requirements. Click here.
Prostate-specific Antigen (PSA) is a protein produced by prostate cells. Therefore, the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post treatment to check if the cancer relapses. PSA testing is an important tool for detecting prostate cancer, which measures the level of PSA in a man’s blood. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. The PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people being affected by prostate cancer. It has more market value in the countries with high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer.
PSA testing is anticipated to reduce the likelihood of death from prostate cancer. Refinements of the prostate-specific antigen (PSA) test have been developed to reduce the number of false positive results. Therefore, due to the rising prevalence of prostate cancer, the market is expected to witness high growth rate, over the forecast period.
To understand key trends, Download Sample Report
Prostate cancer is considered as one of the most common cancers among American men, and more than 60% of all prostate cancers are diagnosed in men older than 65. According to the American Cancer Society’s, 2019, there are about 174,650 new cases of prostate cancer accounting for 31,620 deaths. Hence, it is considered to have an early diagnosis of the condition. In case of the treatment, the early stages of prostate cancer are treated by radiation therapy and for the late stages, where it has spread beyond the prostate gland, hormone therapy, chemotherapy, and or immunotherapy treatments, are recommended. In the case of benign prostatic hyperplasia (BPH), resectoscopy is the major treatment procedure. Zytiga and Xtandi are the major therapeutics that are used for treatment. Zytiga is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). With promising pipeline drugs, such as Apalutamide, the market of therapeutics is expected to increase.
To understand geography trends, Download Sample Report.
Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc, Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG, among others.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
4.2.3 Increasing Government Initiatives for Cancer Awareness
4.3 Market Restraints
4.3.1 High Cost of Prostate Cancer Drugs
4.3.2 Low Success Rate of Clinical Trials
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type
5.1.1 Benign Prostatic Hyperplasia
5.1.2 Prostatic Adenocarcinoma
5.1.3 Small Cell Carcinoma
5.1.4 Other Types
5.2 By Modality
18.104.22.168 Tissue Biopsy
22.214.171.124 Transrectal Ultrasound
126.96.36.199 Clinical Laboratory Examination
188.8.131.52.1 Prostate-specific Antigen Testing
184.108.40.206.2 Urine Testing
220.127.116.11 Diagnostic Imaging
18.104.22.168 Radiation Therapy
22.214.171.124.1 Hormone Therapy
126.96.36.199.3 Other Treatments
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Ipsen SA
6.1.2 Bayer AG
6.1.3 Astellas Pharma Inc.
6.1.4 Abbvie Inc.
6.1.5 Dendreon Pharmaceuticals LLC
6.1.6 AstraZeneca PLC
6.1.8 Tolmar Inc.
6.1.9 Koninklijke Philips NV
6.1.10 Hologic Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments